Recent Developments in Microbiome Therapeutics Recent-Developments-in-Microbiome-Therapeutics-Nov

Table 2: Overview of Publicly listed companies Company Seres Therapeutics 4D Pharma PLC Synthetic Biologics Location USA UK USA Infant Bacterial Sweden Therapeutics AB 18 Market Cap $403,910,000 $252,910,000 $100,930,000 $88,000,000 Disease Indications Lead Candidate Recurrent C. difficile Infection SER-109 Primary C. difficile Infection SER-262 Ulcerative Colitis SER-287 Inflammatory Bowel Disease SER-301 Stage of Development Discovery Preclinical Clinical Phase 1 Phase 2 Phase 3 Prevention of infection and GVHD following hematopoietic stem cell or organ SER-155 transplant Immuno-oncology and hematopoietic stem cell transplant – Inflammatory Bowel Disease – Primary sclerosing cholangitis, NASH and other liver diseases – Obesity/Metabolic syndrome – Genetic metabolic diseases – Irritable Bowel Syndrome Blautix Paediatric Crohn’s disease Thetanix Paediatric Ulcerative Colitis Rosburix Cancer MRx518 Severe neutrophilic asthma MRx0004 Eosinophilic asthma MRx0001 Rheumatoid arthritis MRx0006 Multiple sclerosis MRx0002 Autism – Anxiety/depression – Primary C. difficile Infection, Pathogenic overgrowth, Antimicrobial Resistance SYN-004 (Ribaxamase) Irritable Bowel Syndrome with constipation SYN-010 Pertussis (Whooping Cough) SYN-005 Phenylketonuria (PKU) SYN-200 Necrotizing Enterocolitis (NEC) IBP-9414 Gastroschisis IBP-1016 Recent Developments in Microbiome Therapeutics

Recent Developments in Microbiome Therapeutics Recent-Developments-in-Microbiome-Therapeutics-Nov | Page 18